ORAL ADMINISTRATION OF MICROENCAPSULATED Limosilactobacillus fermentum CRL1446 IMPROVES THE MAIN BIOMARKERS OF METABOLIC SYNDROME IN MICE

TOMEI, C; MARQUEZ, A; RUSSO, M; ANDRADA, E; MEDINA, R; GAUFFIN-CANO, P

San Miguel de Tucumán

Simposio; VI International Symposium on Lactic Acid Bacteria - I Argentinean-Japanese Lactic Acid Bacteria ?Tohoku Forum for Creativity? Meeting; 2024

Consejo Nacional de Investigaciones Científicas y Técnicas. Centro de Referencia para Lactobacilos

Metabolic syndrome (MS) is one of the most relevant health problems in the world due to the increased consumption of high-fat diets. The probiotic Limosilactobacillus fermentum CRL1446 has been scientifically described for its ability to improve biomarkers of MS. Microencapsulation has become an appropriate technological alternative to protect probiotic microorganisms from drastic conditions of the gastrointestinal tract or the technological process. The work aimed to evaluate the effectiveness of oral administration of microcapsules containing Limosilactobacillus fermentum CRL1446 (CRL1446) on improving nutritional, biochemical, and inflammatory parameters in a mice pre-clinical model in MS. Adult male C57BL/6 mice were fed for 15 weeks and divided into the following groups (n=6): (a) Control group (Cont; mice fed a standard diet [SD]); (b) Metabolic Syndrome (MS; mice fed a high-fat diet [HFD]); (c) MS + Bacteria-free empty microcapsules (Mic); (d) MS + microcapsules containing CRL1446 strain (MicPro; mice fed a HFD plus a daily microcapsule dose in drinking water [1x10^9 CFU/day/mouse]). Body weight was measured weekly. At the end of the study, animals fasted for 12 hours and were subsequently anesthetized and sacrificed. The adiposity index was determined. The following metabolic and inflammatory parameters were evaluated: (a) Lipidic profile: total cholesterol (TC), high-density lipoprotein cholesterol, low-density cholesterol (LDL), and triglycerides (TG) by enzymatic methods; (b) Glycemic profile: plasma glucose levels (enzymatic methods), insulin (ELISA Test), and oral glucose tolerance tests (OGTT); (c) Pro-inflammatory profile: TNF-α and IL-6 cytokines (flow cytometry); and (d) Leptin levels (ELISA Test). The results show that the administration of MicPro did not influence the decrease in body weight or adiposity index. However, metabolic parameters were significantly improved. MicPro induces a significant reduction in TG, TC, and LDL. Likewise, we observed a decrease in glucose and insulin, which allowed significant improvement in OGTT. Also, a significant reduction in the levels of leptin and pro-inflammatory cytokines was observed in response to the treatment. This probiotic strain maintains its hypoglycemic and hypolipidemic properties after the microencapsulation process, which could facilitate their incorporation into different food matrices.